Drug therapies in bronchopulmonary dysplasia: debunking the myths

Seminars in Fetal and Neonatal Medicine

Volumn 14, Issue 6, 2009, Pages 383-390

  Tin, Win ^a   Wiswell, Thomas E ^b  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^b FLORIDA HOSPITAL   (United States)

Author keywords

Bronchopulmonary dysplasia; Chronic lung disease; Drug therapies; Preterm; Respiratory distress syndrome

Indexed keywords

ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETAMETHASONE; BRONCHODILATING AGENT; BUDESONIDE; BUMETANIDE; CAFFEINE; CAFFEINE CITRATE; CHLOROTHIAZIDE; CORTICOSTEROID; DEXAMETHASONE; ERYTHROMYCIN; FLUTICASONE; FUROSEMIDE; IBUPROFEN; INDOMETACIN; INOSITOL; IPRATROPIUM BROMIDE; LUCINACTANT; NITRIC OXIDE; RETINOL; SALBUTAMOL; SILDENAFIL; SPIRONOLACTONE; SUPEROXIDE DISMUTASE; SURFACTANT; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; ANAMNESIS; APNEA; ARTICLE; BONE DEMINERALIZATION; CALCIUM URINE LEVEL; CHRONIC LUNG DISEASE; CLINICAL TRIAL; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; INCIDENCE; INFANCY; INFECTION; KIDNEY CALCIFICATION; LOW DRUG DOSE; LUNG DYSPLASIA; LUNG EDEMA; NERVE CELL DIFFERENTIATION; NONHUMAN; OTOTOXICITY; OXYGEN THERAPY; PATENT DUCTUS ARTERIOSUS; POPULATION; SIDE EFFECT; SURVIVAL; UREAPLASMA INFECTION;

ADRENAL CORTEX HORMONES; ANTIOXIDANTS; BRONCHODILATOR AGENTS; BRONCHOPULMONARY DYSPLASIA; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; PREGNANCY; PULMONARY SURFACTANTS;

EID: 70350757642     PISSN: 1744165X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.siny.2009.08.003     Document Type: Article

References (92)

1. Northway W.H., Rosen R.C., and Porter D.Y. Pulmonary disease following respiratory therapy of hyaline membrane disease: bronchopulmonary dysplasia. N Engl J Med 276 (1967) 357-368
2. Bancalari E., Claure N., and Sosenko I. Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition. Semin Neonatol 8 (2003) 63-71
3. Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev (2000) CD000065
4. Crowther C.A., and Harding J. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease. Cochrane Database Syst Rev (2003) CD003935
5. Soll R.F. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev (2000) CD001079
6. Soll R.F. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev (2000) CD000511
7. Soll R.F., and Morley C.J. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev (2001) CD000510
8. Soll R.F., and Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev (2001) CD000144
9. Soll R.F. Synthetic surfactant for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev (2000) CD001149
10. Pfister R.H., Soll R.F., and Wiswell T. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst Rev (2007) CD006069
11. Sinha S.K., Lacaze-Masmontiel T., Valls I., et al. A multicentre, randomised controlled trial of lucinactant versus poractant alpha among very premature infants at high risk of respiratory distress syndrome. Pediatrics 115 (2005) 1030-1038
12. Moya F., Gadzinowski J., Bancalari E., et al. A multicentre, randomised, masked, comparison trial of lucinactant, colfosceril palmitate and beractant for the prevention of respiratory distress syndrome. Pediatrics 115 (2005) 1018-1029
13. Henderson-Smart D.J., and Steer P. Methylxanthine treatment for apnoea in preterm infants. Cochrane Database Syst Rev (2001) CD000140
14. In: Hey E. (Ed). Neonatal formulary. 5th ed. (2007), BMJ Books, London
15. Aranda J.V., Gorman W., Bergsteinsson H., and Gunn T. Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. J Pediatr 90 (1977) 467-472
16. Schmidt B. Methylxanthine therapy in premature infants: sound practice, disaster or fruitless by way?. J Pediatr 135 (1999) 526-528
17. Gunn T.R., Metrakos K., Riley P., et al. Sequelae of caffeine treatment in preterm infants with apnea. J Pediatr 94 (1979) 106-109
18. Nelson R.M., and Resnick M.B. Long term outcome of premature infants treated with theophylline. Semin Perinatol 5 (1981) 370-373
19. Ment L.R., Scott D.T., Ehrenkranz R.A., et al. Early childhood developmental follow up of infants with GMH/IVH: effect of methylxanthine therapy. Am J Perinatol 2 (1985) 223-227
20. Kitchen W.H., Doyle L.W., Ford G.W., et al. Cerebral palsy in very low birth weight infants surviving to 2 years with modern neonatal intensive care. Am J Perinatol 4 (1987) 29-35
21. Hoecker C., Nelle M., Poeschl J., et al. Caffeine impairs cerebral and intestinal blood flow velocity in preterm infants. Pediatrics 109 (2002) 784-787
22. Anonymous. New drug application: CAFCIT (NDA) 02073 (2000), Food and Drug Administration, Washington, DC
23. Schmidt B., Roberts R.S., Davis P., et al. Caffeine therapy for apnea of prematurity. N Engl J Med 354 (2006) 2112-2121
24. Schmidt B., Roberts R.S., Davis P., et al. Long term effects of caffeine therapy for apnea of prematurity. N Engl J Med 357 (2007) 1893-1902
25. Davis PG, Schmidt B, Roberts R, et al. Caffeine for Apnea of Prematurity (CAP) Trial: benefits may vary in subgroups. J Pediatr, in press.
26. Saugstad O.D. Bronchopulmonary dysplasia - oxidative stress an anti-oxidants. Semin Neonatol 8 (2003) 39-49
27. Tin W., Milligan D.W.A., Pennefather P., et al. Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child 84 (2001) F106-F110
28. Chow L., Wright K.W., and Sola S. Can changes in clinical practice decrease the incidence of severe retinopathy in very low birth weight infants?. Pediatrics 111 (2003) 339-345
29. Anderson C.G., Benitz W.E., and Madan A. Retinopathy of prematurity and pulse oximetry: a national survey of recent practices. J Perinatol 24 (2004) 164-168
30. Sun S.C. Relation of target SpO2 levels and clinical outcome in ELBW infants on supplemental oxygen. Pediatr Res 51 (2002) A350
31. Poets C., Arand J., Hummler H., et al. Retinopathy of prematurity: a comparison between two centers aiming for different pulse oximetry saturation levels. Biol Neonate 84 (2003) A267
32. Tin W., and Wariyar U. Giving small babies oxygen: 50 years of uncertainty. Semin Neonatol 7 (2002) 361-367
33. Silverman W.A. A cautionary tale about supplemental oxygen: the albatross of neonatal medicine. Pediatrics 113 (2004) 394-396
34. Kang J.L., Park W., Pack I.S., et al. Inhaled nitric oxide attenuates acute lung injury via inhibition of nuclear factor-kappa B and inflammation. J Appl Physiol 92 (2002) 795-801
35. Ballard P.L., Gonzales L.W., Godinez R.I., et al. Surfactant composition and function in a primate model of infant chronic lung disease: effect of inhaled nitric oxide. Pediatr Res 59 (2006) 157-162
36. McCurnin D.C., Pierce R.A., Chang L.Y., et al. Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease. Am J Physiol Lung Cell Mol Physiol 288 (2005) L450-L459
37. Finer N., and Barrington K.J. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev (2006) CD000339
38. Barrington K.J., and Finer N.N. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev (2007) CD000509
39. Kinsella J.P., Walsh W.F., Bose C.L., et al. Inhaled nitric oxide in premature neonates with severe hypoxemic respiratory failure: a randomised controlled trial. Lancet 354 (1999) 1061-1065
40. Anonymous. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. The Franco-Belgium Collaborative NO Trial Group. Lancet 354 (1999) 1066-1071
41. Subhedar N.V., Ryan S.W., and Shaw N.J. Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Arch Dis Child 77 (1997) F185-F190
42. Field D., Elbourne D., Truesdale A., et al. Neonatal ventilation with inhaled nitric oxide versus ventilatory support without inhaled nitric oxide for preterm infants with severe respiratory failure: the INNOVO Multicentre Randomised Controlled Trial. Pediatrics 115 (2005) 926-936
43. Van Meurs K.P., Wright L.L., Ehrenkranz R.A., et al. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med 353 (2005) 13-22
44. Schreiber M.D., Gin-Mestan K., Marks J.D., et al. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 349 (2003) 2099-2107
45. Kinsella J.P., Cutter G.R., Walsh W.F., et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med 355 (2006) 354-364
46. Ballard R.A., Truog W.E., Cnann A., et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 355 (2006) 343-353
47. Mercier J., Hummler H., Dummeyer X., et al. Inhaled nitric oxide (iNO) for prevention of bronchopulmonary dysplasia (BPD) in preterm infants. The EUNO Trial. EPAS (2009) 3212.5
48. Halliday H.L., Ehrenkranz R.A., and Doyle L.W. Early (<96 hours) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 1 (2003) CD001146
49. Halliday H.L., Ehrenkranz R.A., and Doyle L.W. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 1 (2003) CD001144
50. Halliday H.L., Ehrenkranz R.A., and Doyle L.W. Delayed (> 3 weeks) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 1 (2003) CD001145
51. Cummings J.J., D'Eugenio D.B., and Gross S.J. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med 320 (1989) 1505-1510
52. O'Shea T.M., Kothadia J.M., and Klinepeter K.L. Randomised placebo controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 104 (1995) 15-21
53. Yeh T.F., Lin Y.J., and Huang C.C. Early dexamethasone therapy in preterm infants: a follow up study. Pediatrics 101 (1998) E7
54. Shinwell E.S., Karplus M., and Reich D. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child 83 (2000) F177-F181
55. American Academy of Pediatrics, Committee on Fetus and Newborn, Canadian Pediatric Society, and Fetus and Newborn Committee. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 109 (2002) 330-338
56. Halliday H.L. Guidelines on neonatal steroids. Prenat Neonat Med 6 (2001) 371-373
57. Doyle L.W., Davis P.G., Morley C.J., et al. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomised, controlled trial. Pediatrics 117 (2006) 75-83
58. Doyle L.W., Davis P.G., Morley C.J., et al. Outcome at 2 years of age of infants from the DART Study: a multicenter, international, randomised controlled trial of low-dose dexamethasone. Pediatrics 119 (2007) 716-721
59. Groneck P., Reuss D., and Gotze-Speer B. Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease. J Pediatr 122 (1993) 938-944
60. Zimmerman J.J., Gabbert D., and Shivpuri C. Meter-dosed, inhaled beclomethasone attenuates bronchoalveolar oxyradical inflammation in premature infants at risk for bronchopulmonary dysplasia. Am J Perinatol 15 (1998) 567-576
61. Merz U., Kusenbach G., and Hausler M. Inhaled budesonide in ventilator-dependent preterm infants: a randomised double-blind pilot study. Biol Neonate 75 (1999) 46-53
62. Shah V., Ohlsson A., Halliday H.L., and Dunn M. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev (2007) CD001969
63. Shah S.S., Ohlsson A., Halliday H.L., et al. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev (2003) CD002058
64. Tyson J.E., Wright L.L., Oh W., et al. Vitamin A supplementation for extremely-low-birth infants. N Engl J Med 340 (1999) 1962-1968
65. Wardle S.P., Hughes A., Chen S., et al. Randomised controlled trial of vitamin A supplementation in preterm infants to prevent chronic lung disease. Arch Dis Child 84 (2001) F9-13
66. Darlow B.A., and Graham P.J. Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birth weight infants. Cochrane Database Syst Rev 4 (2007) CD000501
67. Brion L.P., Bell E.F., and Rughuveer T.S. Vitamin E supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst Rev 4 (2003) CD003665
68. Suresh G., Davis J.M., and Soll R. Superoxide dismutase for preventing chronic lung disease in mechanically ventilated infants. Cochrane Database Syst Rev (2001) CD001968
69. Ng G.Y., da Silva O., and Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database Syst Rev 3 (2001) CD003214
70. Holt W.J., Greenspan J.S., Wiswell T.E., et al. Pulmonary response to an inhaled bronchodilator in chronically ventilated preterm infants with bronchopulmonary dysplasia. Respir Care 40 (1995) 145-151
71. Wilkie R.A., and Bryan M.H. Effect of bronchodilators on airway resistance in ventilator-dependent neonates with chronic lung disease. J Pediatr 111 (1987) 278-282
72. Brundage K.L., Mohsini K.G., Froese A.B., et al. Bronchodilator response to ipratropium bromide in infants with bronchpulmonary dysplasia. Am Rev Respir Dis 142 (1990) 1137-1142
73. Yuksel B., and Greenough A. Ipratropium bromide for symptomatic preterm infants. Eur J Pediatr 150 (1991) 854-857
74. Brion L.P., and Soll R.F. Diuretics for respiratory distress syndrome in premature infants. Cochrane Database Syst Rev (2001) CD001454
75. Schmidt B., Davis P., Moddemann D., et al. Long term effects of indomethacin prophylaxis in extremely-low-birth weight infants. N Engl J Med 344 (2001) 1966-1972
76. Fowlie P.W., and Davis P.G. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev (2002) CD000174
77. Shah S.S., and Ohlsson A. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev (2006) CD004213
78. Howlett A., and Ohlsson A. Inositol for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev (2003) CD000366
79. Mabanta C.G., Pryhuber G.S., Weinburg G.A., et al. Erythromycin for the prevention of chronic lung disease in intubated preterm infants at high risk for, or colonised or infected with Ureaplasma urealyticum. Cochrane Database Syst Rev (2003) CD003744
80. Bancalari E., Abdenour G.E., Feller R., et al. Bronchopulmonary dysplasia: clinical presentation. J Pediatr 85 (1979) 819-823
81. Jobe A., and Bancalari E. NICHD/NHLBI/ORD workshop summary - bronchpulmonary dysplasia. Am J Respir Crit Care Med 163 (2001) 1723-1729
82. Walsh M., Yao Q., Gettner P., et al. Impact of a physiologic definition on bronchpulmonary dysplasia rates. Pediatrics 114 (2004) 1305-1311
83. The STOP-ROP Multicenter Study Group. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 105 (2000) 295-310
84. Askie L.M., Henderson-Smart D.J., Irwig L., et al. Oxygen-saturation targets and outcomes in extremely preterm infants. N Engl J Med 349 (2003) 959-967
85. Brion L.P., and Primhak R.A. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev (2002) CD001453
86. Brion L.P., Primhak R.A., and Yong W. Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev (2006) CD001694
87. Brion L.P., Primhak R.A., and Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev (2002) CD001817
88. Halliday H.L., Ehrenkranz R.A., and Doyle L. Late (>7days) postnatal steroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev (2009) CD001145
89. Doyle L.W., Halliday H.L., Ehrenkranz R.A., et al. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics 115 (2005) 655-661
90. Shah S.S., Ohlsson A., Halliday H.L., et al. Inhaled versus systemic corticosteroid for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev (2007) CD002057
91. Ladha F., Bonnet S., and Eaton F. Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. Am J Respir Crit Care Med 172 (2005) 750-756
92. Lai N.M., Rajadurai S.V., and Tan K. Increased energy intake for preterm infants with (or developing) bronchopulmonary dysplasia/chronic lung disease. Cochrane Database Syst Rev (2006) CD005093